The exacerbation of cutaneous psoriasis induced by anti - TNF therapy - case report

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Jun 30, 2014
DOI: https://doi.org/10.22551/2014.01.0101.10006
Anca Costache Mădălina Ionela Chiriac Elena Rezuş
Rheumatology Department, Rehabilitation Hospital, Iasi, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

Abstract

The tumor necrosis factor (TNF) blockers are highly effective therapy for numerous autoimmune inflammatory diseases, including rheumatoid arthritis, psoriatic arthropathy (PsA), spondyloarthropathies, juvenile idiopathic arthritis and inflammatory bowel disease. Paradoxically, these agents can induce cutaneous and systemic autoimmune diseases; the most common are psoriasis skin lesions and systemic lupus erythematosus (SLE) induced by TNF blockers. We present the case of a 59 years-old female, diagnosed at 32 years with cutaneous psoriasis vulgaris and psoriatic arthropathy at 54 years-old. After treatment failure with conventional Disease-Modifying Antirheumatic Drugs (DMARDs), biologic therapy with infliximab was started. After 3 years of treatment, the patient suffers an exacerbation of skin lesions and worsening joint damage. We decided to stop the infliximab and initiate the therapy with another anti-TNF agent (adalimumab), with improvement of the skin lesions and joint manifestations.

##plugins.themes.bootstrap3.article.details##

Keywords

psoriasis, biologic therapy, psoriatic arthropathy, adalimumab

References
1. Ko JM, Gottlieb AB, Kerbleski JF: Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat, 2009, 20(2):100-8.
2. Joyau C, Veyrac G, Dixneuf V, Jolliet P: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol, 2012, 30(5):700-6.
3. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, et al: Psoriasiform and pustular eruption induced by infliximab. J Dermatol, 2007, 34:468–72.
4. Nestle FO, Conrad C, Tun-Kyi A, et al: Plasmacytoid predendritic cells initiate psoriasis through interferon-production. J Exp Med, 2005, 202:135–43.
5. Eriksen KW, Lovato P, Skov L, et al: Increased sensitivity to interferon- in psoriatic T cells. J Invest Dermatol, 2005, 125:936–44.
6. Gilliet M, Conrad C, Geiges M, et al: Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol, 2004, 140:1490–5.
7. Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A: Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol, 2007, 32:176–9.
8. Collamer A N, Battafarano DL: Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: A Literature Review and Potential Mechanisms of Action. Arthritis & Rheumatism (Arthritis Care & Research), 2008, 59(7):996–1001.
How to Cite
Costache, A., Chiriac, M. I., & Rezuş, E. (2014). The exacerbation of cutaneous psoriasis induced by anti - TNF therapy - case report. Archive of Clinical Cases, 1(1), Arch Clin Cases 2014; 1(1):23-27. https://doi.org/10.22551/2014.01.0101.10006
Issue
Vol. 1 No. 1 (2014)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Costache, A., Chiriac, M. I., & Rezuş, E. (2014). The exacerbation of cutaneous psoriasis induced by anti - TNF therapy - case report. Archive of Clinical Cases, 1(1), Arch Clin Cases 2014; 1(1):23-27. https://doi.org/10.22551/2014.01.0101.10006